For instance, a phase III clinical trial of olaparib in prostate cancer involved tumors with identified mutations in BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L genes, and the detection of a single mutational event was sufficient for the administration of this drug. Here, BRCA1 is linked to prostate cancer.